Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

NCT05660980 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

NIH

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Once daily CAB tablet + RPV tablet
DRUG: Long acting CAB injectable + long acting RPV injectable
DRUG: Long acting CAB injectable + long acting RPV injectable

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]